TriNetX与Regeneron合作，访问3亿患者的去标识化电子健康记录，以推动生命科学和数字健康解决方案的研究与产品开发-动脉网

TriNetX Collaborates with Regeneron to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions

PR Newswire 等信源发布 2026-04-03 04:30



可切换为仅中文







Regeneron has exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX's industry-leading global network of electronic health record data

Regeneron有独家机会将大规模基因组学和蛋白质组学数据队列与TriNetX行业领先的全球电子健康记录数据网络连接起来。

Collaboration will expand Regeneron's world-leading genomic and proteomic EHR-linked database

合作将扩展Regeneron世界领先的基因组学和蛋白质组学与电子健康记录（EHR）关联的数据库。

Growing database will continue to drive drug discovery and development and empower AI training algorithms to deliver digital health solutions of the future for consumers, patients and providers

不断增长的数据库将继续推动药物的发现和开发，并为人工智能训练算法赋能，从而为消费者、患者和医疗服务提供者提供未来的数字健康解决方案。

TARRYTOWN, N.Y. and CAMBRIDGE, Mass.

纽约州塔里敦和马萨诸塞州剑桥市

，

April 2, 2026

2026年4月2日

/PRNewswire/ -- TriNetX

and Regeneron Pharmaceuticals, Inc. (NASDAQ:

和再生元制药公司（纳斯达克：

REGN

再生元制药公司

) today announced a strategic collaboration to support Regeneron's capabilities in drug discovery and development, as well as new initiatives to deliver digital health solutions of the future for consumers, patients and providers. Regeneron gains the exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX's industry-leading phenotypic data network of approximately 300 million de-identified and anonymized patients.

）今天宣布了一项战略合作，以支持再生元在药物发现和开发方面的能力，并推出新举措，为消费者、患者和医疗服务提供者提供未来的数字健康解决方案。再生元获得了将大规模基因组和蛋白质组数据队列与TriNetX行业领先的表型数据网络（包含约3亿名去识别化和匿名患者）连接起来的独家机会。

This collaboration will enable expansion of Regeneron's world-leading genomic and proteomic Electronic Health Record (EHR)-linked database, a key driver of the company's industry-leading therapeutics pipeline..

此次合作将扩大再生元公司世界领先的基因组学和蛋白质组学电子健康记录（EHR）关联数据库，这是该公司行业领先的治疗学管线的关键驱动力。

Under the collaboration, TriNetX will provide Regeneron with secure, licensed access to TriNetX's current and future de-identified health data from approximately 300 million individuals (170 million of whom are in the United States), sourced directly from its global network of health system partners.

根据合作协议，TriNetX 将为再生元提供安全、授权的访问权限，访问其来自约 3 亿患者（其中 1.7 亿人在美国）的当前和未来去识别化的健康数据，这些数据直接来源于 TriNetX 的全球医疗系统合作伙伴网络。

With privacy-preserving methods, Regeneron will have the capability to match a portion of TriNetX's de-identified/anonymized data to genomic and proteomic data generated by the .

通过保护隐私的方法，Regeneron 将能够将 TriNetX 部分去标识化/匿名化的数据与由其生成的基因组和蛋白质组数据相匹配。

Regeneron Genetics Center

再生元遗传学中心

(RGC

（RGC

)

. Such matching will be conducted in accordance with all applicable

. 此类匹配将按照所有适用的

data privacy

数据隐私

laws, including HIPAA and GDPR.

法律，包括HIPAA和GDPR。

The RGC has developed high-throughput and cost-efficient DNA sequencing and proteomics approaches to build the world's largest database of EHR-linked sequencing and proteomics data, in collaboration with over 150 life sciences and healthcare collaborators around the world. The collaboration with TriNetX will help Regeneron dramatically expand this already world-leading dataset to continue to drive drug discovery and development, while also empowering .

RGC 已开发出高通量且成本高效的 DNA 测序和蛋白质组学方法，与全球超过 150 家生命科学和医疗领域的合作伙伴携手，构建了全球最大的与电子健康记录（EHR）关联的测序和蛋白质组学数据库。与 TriNetX 的合作将帮助再生元大幅扩展这一已经处于世界领先地位的数据集，进一步推动药物发现与开发，同时也为赋能提供支持。

artificial intelligence

人工智能

(AI) training algorithms to deliver digital health solutions of the future.

(AI) 训练算法，以提供未来的数字健康解决方案。

'We are delighted to work with Regeneron, and specifically the Regeneron Genetics Center team, to advance human health through the application of intelligence-driven information technology, powered by our trusted data,' said Jeff Margolis, TriNetX Executive Chairman. 'Our team is gratified to be selected by Regeneron to provide access to TriNetX's unique breadth and depth of research-ready data, across our extensive federated global network of academic medical centers and other leading healthcare research sites.'.

“我们很高兴与Regeneron合作，特别是与Regeneron遗传学中心团队合作，通过应用由我们可靠数据支持的智能驱动信息技术来促进人类健康，”TriNetX执行主席Jeff Margolis表示。“我们的团队很荣幸被Regeneron选中，提供访问TriNetX独特广度和深度的研究就绪数据的机会，覆盖我们广泛的全球学术医疗中心及其他领先的医疗保健研究站点联合网络。”

'This is a major milestone for the RGC and a powerful new pathway to achieve our core mission: building the world's largest and richest human health database to drive drug development and pioneer digital health solutions for consumers, patients and providers,' said Aris Baras, M.D., Senior Vice President, Head of RGC and Co-head of Regeneron Genetic Medicines.

“这是RGC的一个重要里程碑，也是实现我们核心使命的一条强有力的新途径：建立全球最大、最丰富的人类健康数据库，以推动药物开发，并为消费者、患者和医疗服务提供者开创数字健康解决方案，”RGC负责人、再生元遗传医学联合主管、高级副总裁阿里斯·巴拉斯博士表示。

'TriNetX has built a world-leading platform with a proven track record of enabling research at scale. The RGC has spent over a decade generating genomic and now proteomic data and integrating these molecular data with longitudinal health records at large-scale. Combining these platforms brings together powerful human health databases with analytical and AI capabilities to help discover and develop innovative medicines for devastating diseases and create digital health solutions that we hope will transform our ability to predict, prevent and manage disease.'.

“TriNetX打造了世界领先的平台，在大规模研究方面有着经验证的成功记录。RGC花费了十多年的时间生成基因组数据，现在是蛋白质组数据，并将这些分子数据与大规模的纵向健康记录整合在一起。结合这些平台，可以将强大的人类健康数据库与分析和人工智能能力结合起来，有助于发现和开发针对毁灭性疾病的创新药物，并创建数字健康解决方案，我们希望这将改变我们预测、预防和管理疾病的能力。”

'We are looking forward to working with the TriNetX team,' said Andrew Deubler, Senior Vice President, RGC Chief Business and Administrative Officer. 'Our RGC strategic investments catalyze innovation, driving advancements in cutting-edge technologies that accelerate drug discovery and development, as well as help us develop innovative digital health solutions.

“我们期待与TriNetX团队合作，”RGC首席业务和行政官、高级副总裁安德鲁·德布勒表示。“我们的RGC战略投资推动创新，促进尖端技术的发展，从而加速药物的发现与开发，并帮助我们开发创新的数字健康解决方案。”

This deal represents the latest and one of our most significant collaborations, and we look forward to continuing to expand our network of top-tier partners as we pursue our mission.'.

这项交易代表了我们最新和最重要的合作之一，我们期待在追求使命的过程中继续扩展我们的顶级合作伙伴网络。

As part of the collaboration, Regeneron will invest up to $200 million in TriNetX.

作为合作的一部分，Regeneron将向TriNetX投资高达2亿美元。

About TriNetX, LLC

关于TriNetX有限责任公司

TriNetX is the Global Truth Engine for Better Human Health™ that makes complex, real-world health data easy to use. Data is sourced directly from our growing global network of over 11,000 healthcare provider locations. TriNetX customers select the data source, types, and breadth of data they need; the data access methods they desire; and the types of software, human and machine intelligence they wish to apply – and combine these to solve their business objectives.

TriNetX 是全球领先的“更好人类健康™”真实数据引擎，它使复杂的现实世界健康数据易于使用。数据直接来源于我们不断扩展的全球网络，涵盖超过11,000个医疗保健提供方地点。TriNetX 的客户可以选择所需的数据来源、类型和广度；期望的数据访问方式；以及希望应用的软件、人类和机器智能类型，并将这些结合起来实现其业务目标。

Visit TriNetX at .

访问 TriNetX。

www.trinetx.com

or follow TriNetX on

或关注TriNetX

领英

to learn more.

了解更多。

About Regeneron

关于再生元

Regeneron (NASDAQ:

再生元（纳斯达克：

REGN

再生元制药（Regeneron Pharmaceuticals）

) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories.

）是一家领先的生物技术公司，为患有严重疾病的患者发明、开发和商业化改变生命的药物。公司由医生科学家创立并领导，我们独特的能力在于能够反复且持续地将科学转化为医学，目前已研发出众多获批的治疗方法和正在开发的产品候选药物，其中大部分都是在我们自己的实验室中自主研发的。

Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. .

我们的药物和研发管线旨在帮助患有眼疾、过敏性和炎症性疾病、癌症、心血管和代谢疾病、神经性疾病、血液病、传染病以及罕见病的患者。

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as

Regeneron利用我们的专有技术，如...推动科学发现的边界并加速药物开发。

VelociSuite

速度套件

, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center

，该公司生产优化的全人源抗体和新型双特异性抗体。我们正利用来自再生元遗传学中心的数据驱动洞察力，塑造医学的下一个前沿领域。

and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.

以及开创性的基因药物平台，使我们能够识别创新靶点和互补方法，有望治疗或治愈疾病。

For more information, please visit

有关更多信息，请访问

www.Regeneron.com

再生元制药公司官网

or follow Regeneron on

或关注再生元公司

领英

，

Instagram

，

Facebook

，

YouTube

或

。

About the Regeneron Genetics Center

关于再生元遗传学中心

The Regeneron Genetics Center

再生元遗传学中心

(RGC

（RGC

) is a genomic research initiative and a wholly owned subsidiary of Regeneron. For over a decade, we have harnessed the power of human genetics to discover important new medicines, validate existing research programs and optimize clinical trials. We tap into our growing database of more than 3 million sequenced exomes and de-identified health information using proprietary data analytics, technology and human ingenuity to make meaningful biological discoveries at speed and scale.

）是一项基因组研究计划，也是再生元的全资子公司。十多年来，我们利用人类遗传学的力量发现了许多重要的新药，验证了现有的研究项目并优化了临床试验。我们通过专有的数据分析、技术和人类智慧，挖掘不断增长的数据库，其中包含超过300万个已测序的外显子组和去标识化的健康信息，从而快速且大规模地做出有意义的生物学发现。

Our high-touch integrated model focuses on working closely with our collaborators to build a dataset with meaningful cohorts. We use innovative technologies, such as machine learning, to sequence exomes, align with health information and perform large-scale analyses to make meaningful associations between genes and diseases.

我们的高接触度整合模型专注于与合作伙伴密切合作，构建具有有意义队列的数据集。我们使用创新技术（如机器学习）对外显子进行测序，与健康信息对齐，并进行大规模分析，以建立基因与疾病之间的有意义关联。

We apply our insights to guide Regeneron's broader drug discovery and development efforts..

我们将运用我们的见解来指导再生元更广泛的药物发现和开发工作。

Regeneron Forward-Looking Statements and Use of Digital Media

再生元前瞻性声明与数字媒体的使用

This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ('Regeneron' or the 'Company'), and actual events or results may differ materially from these forward-looking statements.

本新闻稿包含涉及再生元制药公司（“再生元”或“公司”）未来事件和未来表现的前瞻性声明，这些声明存在风险和不确定性，实际事件或结果可能与这些前瞻性声明有重大差异。

Words such as 'anticipate,' 'expect,' 'intend,' 'plan,' 'believe,' 'seek,' 'estimate,' variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, 'Regeneron's Products') and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, 'Regeneron's Product Candidates'), research and clinical programs now underway or planned, and the use of human genetics in Regeneron's research programs; the likelihood, timing, and scope of achieving any of the anticipated milestones described in this press release; the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees (such as those that may result from Regeneron's collaboration with TriNetX discussed in this press release) may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; ongoing regulatory obligations and oversight impacting Regeneron's Products, research and clinical programs, and business, including those relating to patient pri.

诸如“预期”、“预计”、“打算”、“计划”、“相信”、“寻求”、“估计”之类的词语及其变体和类似的表达旨在识别这些前瞻性陈述，尽管并非所有前瞻性陈述都包含这些识别词。这些陈述涉及，并且这些风险和不确定性包括：再生元及其合作者或许可方（统称为“再生元的产品”）已上市或商业化的、以及正在开发中的产品候选者（统称为“再生元的产品候选者”）的性质、时间安排、可能的成功及治疗应用；当前正在进行或计划中的研究和临床项目；以及人类遗传学在再生元研究项目中的应用；本新闻稿中描述的预期里程碑实现的可能性、时间和范围；由再生元及其合作者或许可方进行的研发项目结果（例如，本新闻稿中讨论的与TriNetX合作可能产生的结果）在其他研究中被复制和/或推动产品候选者进入临床试验、治疗应用或获得监管批准的可能性；影响再生元产品、研究和临床项目及其业务的持续监管义务和监督，包括与患者相关的那些。

(aflibercept) Injection), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron's business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron's filings with the U.S.

（阿柏西普）注射剂）、任何此类诉讼和调查的最终结果，以及上述任何一项可能对再生元的业务、前景、经营结果和财务状况产生的影响。更完整的描述可以在再生元向美国证券交易委员会提交的文件中找到。

Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2025. Any forward-looking statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise..

美国证券交易委员会，包括其截至2025年12月31日的年度Form 10-K。任何前瞻性陈述均基于管理层当前的信念和判断，读者应注意不要依赖再生元公司所做的任何前瞻性陈述。再生元不承担任何更新（无论是公开还是其他方式）任何前瞻性陈述的义务，包括但不限于任何财务预测或指引，无论是否因新信息、未来事件或其他原因。

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (.

再生元利用其媒体和投资者关系网站以及社交媒体渠道发布有关公司的重大信息，其中可能包含对投资者而言属重要的信息。有关再生元的财务及其他信息会定期发布，并可在其媒体和投资者关系网站上查阅。

https://investor.regeneron.com

) and its LinkedIn page (

）及其LinkedIn页面（

https://www.linkedin.com/company/regeneron-pharmaceuticals

）。

Regeneron

再生元

Media:

媒体：

Ella Campbell

埃拉·坎贝尔